Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€108.00

€108.00

-0.460%
-0.5
-0.460%
€92.50
 
25.08.25 / Tradegate WKN: 907122 / Symbol: NVS / Name: Novartis / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Novartis AG ADR Stock

Novartis AG ADR shows a slight decrease today, losing -€0.500 (-0.460%) compared to yesterday.
Based on 3 Buy predictions and 3 Sell predictions the sentiment towards Novartis AG ADR is rather balanced.
A slightly negative potential of -14.81% at a current price of 108.0 € for Novartis AG ADR is the result of a target price of 92 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Novartis AG ADR stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Novartis AG ADR in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novartis AG ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novartis AG ADR -0.460% 1.408% 7.463% 1.887% 14.407% 29.187% 46.939%
Roche Holding AG ADR 0.310% 1.862% -0.990% -7.230% 3.902% -16.995% -6.432%
Bayer AG ADR -4.230% -1.449% -3.546% 0.000% 37.097% -48.872% -52.113%
Astrazeneca ADR -2.160% 1.471% 11.290% -10.968% 7.813% 0.583% 43.154%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.

Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.

Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.

Comments

Novartis AG (NYSE: NVS) was upgraded by analysts at BNP Paribas to a "strong-buy" rating.
Ratings data for NVS provided by MarketBeat
Show more

Novartis AG (NYSE: NVS) had its "underweight" rating re-affirmed by analysts at Barclays PLC.
Ratings data for NVS provided by MarketBeat
Show more

Novartis AG (NYSE: NVS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for NVS provided by MarketBeat
Show more

News

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm: https://g.foolcdn.com/editorial/images/829554/businessperson-and-doctor-talking.jpg
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar

2 Dividend Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/828984/person-sitting-and-working-at-a-desk.jpg
2 Dividend Stocks to Buy and Hold

We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.: https://g.foolcdn.com/editorial/images/825248/pharmacist-talking-to-patient.jpg
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the